MedTrace Logo

Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study

NCT02559960 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2021-04-08

No results posted yet for this study

Summary

This registry aims to monitor the safety of Breviscapine Powder-Injection and to identify the potential risk factors for the adverse drug reactions.

Conditions

  • Adverse Drug Event
  • Adverse Drug Reaction
  • Chinese Medicine
  • Anaphylactic Reaction

Interventions

DRUG

Breviscapine Powder-Injection

Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.

Sponsors & Collaborators

  • Zhong Wang

    lead OTHER

Principal Investigators

  • Zhong Wang, M.D. · China Academy of Chinese Medical Sciences

  • Xin-zhi Wang · The First Hospital of Henan College of Traditional Chinese Medicine

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-08-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02559960 on ClinicalTrials.gov